Ş. A. KORKMAZ Et Al. , "Real-World Evidence of Antipsychotic Monotherapy Versus Polypharmacy in the Treatment of Schizophrenia Spectrum Disorders," Journal of clinical psychopharmacology , vol.44, no.3, pp.250-257, 2024
KORKMAZ, Ş. A. Et Al. 2024. Real-World Evidence of Antipsychotic Monotherapy Versus Polypharmacy in the Treatment of Schizophrenia Spectrum Disorders. Journal of clinical psychopharmacology , vol.44, no.3 , 250-257.
KORKMAZ, Ş. A., Koca, E., Yilmaz, Ö., Özbek, T., Güçlü, M. A., & Kizgin, S., (2024). Real-World Evidence of Antipsychotic Monotherapy Versus Polypharmacy in the Treatment of Schizophrenia Spectrum Disorders. Journal of clinical psychopharmacology , vol.44, no.3, 250-257.
KORKMAZ, ŞÜKRÜ Et Al. "Real-World Evidence of Antipsychotic Monotherapy Versus Polypharmacy in the Treatment of Schizophrenia Spectrum Disorders," Journal of clinical psychopharmacology , vol.44, no.3, 250-257, 2024
KORKMAZ, ŞÜKRÜ A. Et Al. "Real-World Evidence of Antipsychotic Monotherapy Versus Polypharmacy in the Treatment of Schizophrenia Spectrum Disorders." Journal of clinical psychopharmacology , vol.44, no.3, pp.250-257, 2024
KORKMAZ, Ş. A. Et Al. (2024) . "Real-World Evidence of Antipsychotic Monotherapy Versus Polypharmacy in the Treatment of Schizophrenia Spectrum Disorders." Journal of clinical psychopharmacology , vol.44, no.3, pp.250-257.
@article{article, author={ŞÜKRÜ ALPEREN KORKMAZ Et Al. }, title={Real-World Evidence of Antipsychotic Monotherapy Versus Polypharmacy in the Treatment of Schizophrenia Spectrum Disorders}, journal={Journal of clinical psychopharmacology}, year=2024, pages={250-257} }